April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Prevention of Post-Photocoagulation Related Macular Edema by Intravitreal Bevacizumab
Author Affiliations & Notes
  • E. Torres-Porras
    Retina, Asociación para Evitar la Ceguera en Mexico, Mexico, Mexico
  • O. Burgos-Vejar
    Retina, Asociación para Evitar la Ceguera en Mexico, Mexico, Mexico
  • H. Ruiz-García
    Retina, Asociación para Evitar la Ceguera en Mexico, Mexico, Mexico
  • R. Velez-Montoya
    Retina, Asociación para Evitar la Ceguera en Mexico, Mexico, Mexico
  • A. Pérez-Montesinos
    Retina, Asociación para Evitar la Ceguera en Mexico, Mexico, Mexico
  • D. Rascón-Vargas
    Retina, Asociación para Evitar la Ceguera en Mexico, Mexico, Mexico
  • V. Franco-Cárdenas
    Retina, Asociación para Evitar la Ceguera en Mexico, Mexico, Mexico
  • G. García-Aguirre
    Retina, Asociación para Evitar la Ceguera en Mexico, Mexico, Mexico
  • J. Dalma-Weiszhausz
    Retina, Asociación para Evitar la Ceguera en Mexico, Mexico, Mexico
  • V. Morales-Cantón
    Retina, Asociación para Evitar la Ceguera en Mexico, Mexico, Mexico
  • Footnotes
    Commercial Relationships  E. Torres-Porras, None; O. Burgos-Vejar, None; H. Ruiz-García, None; R. Velez-Montoya, None; A. Pérez-Montesinos, None; D. Rascón-Vargas, None; V. Franco-Cárdenas, None; G. García-Aguirre, None; J. Dalma-Weiszhausz, None; V. Morales-Cantón, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 225. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Torres-Porras, O. Burgos-Vejar, H. Ruiz-García, R. Velez-Montoya, A. Pérez-Montesinos, D. Rascón-Vargas, V. Franco-Cárdenas, G. García-Aguirre, J. Dalma-Weiszhausz, V. Morales-Cantón; Prevention of Post-Photocoagulation Related Macular Edema by Intravitreal Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2009;50(13):225.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess the efficacy of intravitreal bevacizumab in preventing macular edema secondary to panretinal photocoagulation (PRP) in patients with proliferative diabetic retiniopathy (PDR).

Methods: : We enrolled 8 patients with PDR and no macular edema. One randomly selected eye received a single bevacizumab dose between laser sessions. We measured the central retinal thickness (CRT) by Optical Coherence Tomography (OCT) and the best corrected visual acuity (BCVA) in ETDRS charts at base line and 12 weeks after PRP completion.

Results: : Average BCVA of the injected eye at baseline was 75.6±6.6 letters which improved to 79.5±8.5 12 weeks post treatment. The fellow eye showed a baseline BCVA of 79.0±9.1 letters and 80.7±2.5. 12 weeks post treatment. Average CRT in the injected eye at baseline: 208.38±28.7 µm, 12 weeks: 222.0±16.8 µm. Fellow-eye: 193.75±29.8 µm, 12 week: 206.25±23.6µm. There were no statistically significant differences between any of the measurements. (p > 0.05).

Conclusions: : There appears to be no difference between a single intravitreal dose of bevacizumab and no treatment in preventing macular edema secondary to PRP. A greater number of patients are required before more specific conclusions can be drawn.

Clinical Trial: : www.clinicaltrials.gov NCT00801866

Keywords: macula/fovea • edema • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×